Protocol Ledger

NCT07890415 · Phase III · RECRUITING

Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis

Interventional Phase III clinical trial protocol NCT07890415 sponsored by Memorial Sloan Kettering Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-10-15 Enrollment: 14,000 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07890415
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)14,000 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07890415
Protocol FieldVerified Registry Value
NCT IdentifierNCT07890415
Consolidated Lead SponsorMemorial Sloan Kettering Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment14,000 participants (ESTIMATED)
Registered Start Date2026-10-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07890415
Hospital Research SiteLocationSite Profile
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->
Memorial Sloan Kettering Cancer CenterNew York, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Memorial Sloan Kettering Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI